Treatment options after sorafenib failure in patients with hepatocellular carcinoma
Clinical and Molecular Hepatology
;
: 273-279, 2017.
Artigo
em Inglês
| WPRIM
| ID: wpr-216539
ABSTRACT
Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because of the modest net benefit sorafenib has contributed, and rising incidence of hepatocellular carcinoma in the world, continued efforts are ongoing to look for efficient upfront, second line, or combination therapies. Herein we review the most relevant to date published literature on treatment options beyond sorafenib, reported studies, ongoing investigational efforts, and possibilities for future studies in advanced hepatocellular carcinoma.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Prognóstico
/
Incidência
/
Carcinoma Hepatocelular
/
Imunoterapia
Tipo de estudo:
Estudo de incidência
/
Estudo prognóstico
Limite:
Humanos
Idioma:
Inglês
Revista:
Clinical and Molecular Hepatology
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS